- Open Access
Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity
© Di Domenico et al; licensee BioMed Central Ltd. 2009
- Received: 26 September 2008
- Accepted: 08 January 2009
- Published: 08 January 2009
Melanin synthesis, the elective trait of melanocytes, is regulated by tyrosinase activity. In tyrosinase-positive amelanotic melanomas this rate limiting enzyme is inactive because of acidic endo-melanosomal pH. The E5 oncogene of the Human Papillomavirus Type 16 is a small transmembrane protein with a weak transforming activity and a role during the early steps of viral infections. E5 has been shown to interact with 16 kDa subunit C of the trans-membrane Vacuolar ATPase proton pump ultimately resulting in its functional suppressions. However, the cellular effects of such an interaction are still under debate. With this work we intended to explore whether the HPV16 E5 oncoprotein does indeed interact with the vacuolar ATPase proton pump once expressed in intact human cells and whether this interaction has functional consequences on cell metabolism and phenotype.
The expression of the HPV16-E5 oncoproteins was induced in two Tyrosinase-positive amelanotic melanomas (the cell lines FRM and M14) by a retroviral expression construct. Modulation of the intracellular pH was measured with Acridine orange and fluorescence microscopy. Expression of tyrosinase and its activity was followed by RT-PCR, Western Blot and enzyme assay. The anchorage-independence growth and the metabolic activity of E5 expressing cells were also monitored.
We provide evidence that in the E5 expressing cells interaction between E5 and V-ATPase determines an increase of endo-cellular pH. The cellular alkalinisation in turn leads to the post-translational activation of tyrosinase, melanin synthesis and phenotype modulation. These effects are associated with an increased activation of tyrosine analogue anti-blastic drugs.
Once expressed within intact human cells the HPV16-E5 oncoprotein does actually interact with the vacuolar V-ATPase proton pump and this interaction induces a number of functional effects. In amelanotic melanomas these effects can modulate the cell phenotype and can induce a higher sensitivity to tyrosine related anti-blastic drugs.
- Tyrosinase Activity
- Acridine Orange
- Amelanotic Melanoma
- Melanin Deposition
Human Papillomavirus type 16 (HPV-16) is a member of species 9 of the mucosotropic α Papillomavirus genus. Together with a further fifteen α Papillomavirus types, HPV16 is comprised within the so called High Risk anogenital HPV (HR-HPV), that are causally involved in the development of malignant tumors . In particular, HPV 16 is the major etiological agent for cervical cancer and it has also been implicated as a causative agent in a number of carcinomas originating from a variety of other anatomical sites. The oncogenic potentials of HR-HPV types depend on the activity of three transforming genes: E5, E6, and E7. The E6 and E7 proteins are unanimously recognized as the major responsible for virus carcinogenicity [3–5]. Conversely, E5 has been found to have only weak transforming properties and accessory functions [6–8] although indirect evidences point to E5 as an hallmark of HR-HPVs carcinogenicity [9, 10].
HPV-16 E5 is a highly hydrophobic membrane protein, 83 amino acids long, located mainly at the Endoplasmic Reticulum (ER) and to a lesser extent on the Golgi apparatus, the plasma membranes and early endosomes . Its expression induces several cellular changes, including enhanced growth factor signalling , the activation of mitogen-activated protein kinase pathways , anchorage independent growth in immortalized fibroblasts , down regulation of MHC Class I and Class II molecules [15, 16]. Despite the above wide range of activities and in contrast to E5 of Bovine Papillomavirus 1 – one of the first PV oncoproteins to be identified and known as the main oncogene – the biological activities of the HPV16 E5 protein still remain poorly characterized and its role in HPV pathogenesis is far to be understood 
While biochemical interaction of the E5 oncoprotein with the vacuolar H+-ATPase (V-ATPase) is well accepted the cellular effects of this interaction are still under debate. The V-ATPase, the universal proton pump of eukaryotes, is a major modulator of endoplasmic and endosomal pH and through this modulation it regulates the organellar trafficking and functions. It is known that the E5 protein of HPV-16 can interact with the 16 kDa subunit C of the proton pump [11–18] within the ER where most of the E5 is found. Such an interaction prevents the Subunit C from participating in the assembly of the Vacuolar Subcomplex (V0 Subcomplex) that is required for the formation of the mature V-ATPase on the vacuolar membranes . This significantly delays the proteolytic endosomal degradation of the internalized EGFr that eventually recycles to the plasma membrane. This extend the EGFr lifespan and increases the EGF dependent/EGFr signalling [20, 21] suggesting that the interaction with the subunit C represent an elective function of E5. Conversely, other authors believe that the impairment of V-ATPase and consequent delayed degradation of internalized EGFr is an indirect result of trafficking disruption and impaired fusion of early endosomes with late acidic endosomes [22, 23]. The pH modulation is very important in the regulation of cell organellar trafficking and function in many cellular strains. In particular intra-melanosomal pH has been indicated as an essential factor for the control of melanin deposition in melanocytes . Melanogenesis is regulated through the modulation of tyrosinase, the rate-limiting enzyme of the melanogenic pathway. Differences in tyrosinase activity of melanocytes from different skin photo types (Caucasian or Black skin) have been reported . It has also been shown that these differences were not due to variations in tyrosinase abundance or gene activity, but to the regulation of catalytic activity of the enzyme . In fact, near neutral melanosomal pH is optimal for human tyrosinase activity and melanogenesis while melanin production is suppressed in Caucasian melanocytes by low melanosomal pH . Accordingly, tyrosinase mRNA and tyrosinase protein are actually present also in amelanotic melanomas, where no tyrosinase activity and no melanin deposition can be detected [26, 27]. The probable reason of the declined catalytic activity in these cells, where tyrosinase is present in a inactive state, is the low internal pH due to elevated V-ATPase activity consequent to elevated glycolysis and extra-cellular acidification occurring during the metastatic spread. Accordingly, it has been demonstrated that substances that act as selective inhibitors of V-ATPase [28, 29] are able to determine the re-activation of tyrosinase and melanogenesis and melanotic reversion of amelanotic melanomas .
In the present work we expressed the HPV 16 E5 protein in two lines of human, tyrosinase-positive, amelanotic melanomas with the aim to examine whether the E5 expression could modulate the melanosomal pH and tyrosinase activity. Here we provide evidence that HPV-16 E5 protein inhibits proton pump, causing alkalinisation of endocellular pH, tyrosinase activation, melanin deposition and modulation of sensitivity to dopamine mimetic drugs.
Concanamycin A (ConA), 3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), 3,4-dihydroxybenzylamine (DHBA) and buthionine sulfoximine (BSO) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). [3H] tyrosine was purchased from Amersham Biosciences Ltd, Amersham UK). Dulbecco's modified Eagle's medium (DMEM), RPMI 1640 medium and foetal bovine serum (FBS) were purchased from Invitrogen SRL (San Giuliano Milanese, Italy), as well as the SuperScript One-Step RT-PCR System with Platinum Taq DNA Polymerase. The LZRSpBMNZ and the LZRSpBMNZ-E5 plasmids were kindly provided by G. Sibbett (The Beatson Institute for Cancer Research, Glasgow, UK) . All other reagents were analytical grade products.
Two established cell lines of human melanoma, kindly provided by Dr. G. Zupi (Laboratory of Chemotherapy, Regina Elena Institute for Cancer Research, Rome, Italy), were used in the present study: FRM and M14. FRM was recently established from a melanoma patient while M14 is a long established melanoma cell line. Cells were grown in RPMI 1640 medium with 10% (v/v) FBS in humidified incubator with 5% CO2 at 37°C and sub-cultured twice a week at 1:3 and 1:5 split ratio for FRM and M14, respectively. For ConA treatment, cells were seeded at 3.0 × 104 cell/cm2 and allowed to attach overnight. The culture medium was then discarded and replaced with fresh medium containing 10 nM ConA and cells incubated for a further 24 h before the assays.
Phoenix A cells  is a producer cell line for the generation of helper free ecotropic retroviruses. Derived from the 293T Human embryonic kidney line, Phonenix A are highly transfectable using either calcium phosphate or lipid-based transfection protocols and allow the production of infectious progeny within a few days. The presence of an IRES-CD8 surface marker expression cassette downstream of the reading frame of the gag-pol construct offers the advantage to monitor the stability of the producer cell population's ability to produce the gag-pol proteins. Most importantly, both gag-pol and env constructs are under different non Moloney promoters thus minimizing the recombination potential with the introduced retroviral construct. Phoenix A cells were grown in High Glucose DMEM medium supplemented with 10% FBS. Cells were never allowed to reach confluency and were passaged twice a week at a 1:4/1:5 split ratio.
Phoenix A cells were harvested by trypsinization and replated at 3,3 × 104 cell/cm2 in T-75 flasks in complete D-MEM. After 24 h the medium was changed with 13.6 ml of complete D-MEM containing 25 μM Cloroquine diphosphate and the cells were incubated for 30 min at 37°C. At the same time, the DNA Calcium Phosphate co-precipitate mixture was prepared (i.e.: 30 μg of either LZRSpBMNZ or LZRSpBMNZ-E5 plasmid in 0.7 ml 0.25 M CaCl2, successively added with 0.7 ml 50 mM N,N-bis (2-hydroxyethyl)- 2-aminoethansulfonic acid). After 30 min at room temperature, the 1.4 ml Calcium Phosphate mixtures were slowly added to the flasks under delicate agitation. After a 12 h incubation at 37°C in a 5% CO2 atmosphere, the medium was removed, the cells washed once with PBS, added with fresh complete D-MEM and incubated at 32°C with 5% CO2 for 48 h. The medium containing the E5 bearing – or the empty, negative control, -retroviral progenies were removed and centrifuged at 1000 × g for 10 min to pellet cell debris. Clarified supernatant were harvested and either used immediately for infection or aliquoted and stored at -80°C for later use.
24 h before infection, melanoma cells were harvested and replated at 2.0 × 104 cell/cm2 into T-25 flasks. The infection mixtures were prepared by adding 1.5 ml of D-MEM containing either the E5 retrovirus or the empty retrovirus with 1.5 ml of complete D-MEM. Polybrene (5 μg/ml) was then added to each flask directly at the moment of infection. Flasks were then centrifuged at 190 × g for 30 min at room temperature and incubated for 24 h at 32°C in a 5% CO2 atmosphere. The medium was then changed with fresh, complete D-MEM and the cells incubated at 37°C with 5% CO2 for further 48 h. Surviving cells, roughly 40% of the challenged cells, were then washed twice with PBS and replated at 2 × 104 cell/cm2. The efficiency of infection procedure was measured in a pilot experiment by a dilution limit PCR strategy showing an almost even end point for E5 and the single copy beta-globin reference sequence (data not shown). This finding is compatible with an above 50% infection of target cells carrying 1 to 10 copies of proviral DNAs and is in tune with the results expected on the basis of theoretical considerations. The presence of the proviral E5 DNA and of the E5 specific mRNA was confirmed by PCR and RT-PCR as below described. Cells infected with the control retrovirus were briefly referred to as "control cells" throughout the paper.
PCR and RT-PCR
Analyses were performed as previously described . Total DNA and RNA were simultaneously extracted from exponentially growing cell cultures by the Tri-Reagent commercial kit (Molecular Research Centre, Cincinnati, OH) used according to the supplier's instruction. The quality of RNAs was evaluated by the A260/A280 ratio and by visual inspection of ethidium bromide stained formamide agarose gel electrophoresis under UV-B trans-illumination. 1 μg of DNAse digested total RNA and 0.2 μg DNA were amplified in a 50 μl volume of Superscript One-Step (RT)-PCR Platinum TAQ reaction mixture completed with 500 nM up-stream and down-stream primers and 1.5 mM Mg2+. For RT-PCR, the reverse transcription was carried out at 45°C for 30 min. Samples were then heated to 95°C for 150 s to inactivate reverse transcriptase and to activate Platinum TAQ Polymerase. Amplification consisted in 35 cycles under the following conditions. For E5: annealing at 94°C for 50 s, extension at 45°C for 50 s and denaturation at 72°C for 60 s and a final cycle with a 10 min long extension. DNA digested non retrotranscribed negative controls were maintained at +4°C during the RT step and placed in the thermal amplifier at the beginning of RT inactivation step (95°C for 150 s). For tyrosinase: annealing at 52°C for 30 s, extension at 73°C for 60 s and denaturation at 95°C for 45 s and a final cycle with a 5 min long extension. For E5 the E5P65 sense (TGC ATC CAC AAC ATT ACT GGC G) and E5M3AS antisense (AAC ACC TAA ACG CAG AGG CTG C) primers were used; for human tyrosinase the primers were Hu-TYR1 (TTG GCA GAT TGT CTG TAG CC) and Hu-TYR2 (AGG CAT TGT GCA TGC TGC TT) as suggested by Calogero et al. .
Cell viability, cell proliferation and cell specific metabolic activity
Cell viability was measured as already described , Briefly, cells were seeded in 96-well microplates at a density which allowed an exponential growth rate for the following 5 day incubation (i.e. 1.0 × 104/well for M14 and 1.6 × 104/well for FRM). At 24 h intervals the cells were challenged with 1.25 mg/ml MTT in a 100 μl volume of fresh medium containing 0.1% FBS . After 2 h of incubation the monolayers were then decanted, washed twice with PBS and the reduced insoluble dye eluted by 100 μl of isopropanol/HCl 0.04 N. The cell viability was then assessed through the MTT reducing activity evaluated by the A540 – A750 difference measured by a microplate reader (Labsystem Multiscan MS – Thermo Fisher Scientific, Inc. Waltham MA).
Cell proliferation was measured by the growth curve as already described . Briefly, cells were seeded in 96-well microplates at the same density as above. At 24 h intervals the monolayers were stained with Crystal Violet (CV), the dye was eluted by means of 33% acetic acid and the cell number in each well was estimated by the A540 measured in a microplate reader (Labsystem).
Considering that cell viability assay does actually measure the total reducing activity within a tissue culture, and considering that such a global activity may largely vary according to culture conditions, cell environment and phenotypic status, to gain information about a possible modulation of the metabolic activity within E5 expressing cells, the cell specific metabolic activity was calculated. This is the simple MTT/CV absorbance ratio, expressed in arbitrary units, and gives information about the average metabolic activity of single cells.
For each assay a set of at least four different experiment was considered. Each experiment consisted of eight independent replicas.
Acridine orange fluorescent staining
To visualize acidic organelles, Acridine orange (AO) was used . AO is a fluorescent probe that emits green at low concentration and orange at high concentration. To determine the effect of treatments on endocellular compartment pH, cell cultures were seeded onto multiwell microscope slides and allowed to attach overnight. The culture medium was then replaced with non supplemented medium or medium containing 10 nM ConA or medium containing the retrovirus. After 24 h, AO (5 μg/ml) was added and incubation continued for another 20 min. The slides were fixed with 2% formaldehyde in PBS and processed for fluorescence microscopy with a Zeiss 466301 microscope. An Olympus Camedia C5060 was used for colour photography.
Anchorage independent growth assay
A 2 ml of 0.5% agarose gel in RPMI at 10% FCS was poured in each 35 mm well of a plastic plate and allowed to solidify at room temperature for 2 hours in a laminar flow hood. Then a 0.5 ml of a 0.33% agarose gel containing 250 cells was overlaid on top, allowed to stand for 30' at +4°C and subsequently incubated at 37°C. After a 12–16 days incubation the cell growth was evaluated by bright field observation under low magnification and growing colonies photographed.
Western blot analysis
Immunoblot analysis was performed as previously described . Cell lysis was carried out at 4°C by sonication for 1 min in Media I (0.32 M sucrose, 10 mM Tris-HCl, pH 8.0, 0.1 mM MgCl2, 0.1 mM EDTA, 1 mM phenyl-methyl-sulfonyl-fluoride (PMSF) and 10 μg/ml aprotinine) and lysates were stored at -70°C until use. Protein content was determined by the Bio-Rad Protein Assay (Bio-Rad Laboratories Srl, Segrate, Italy). Proteins were separated by 12% SDS-PAGE and transferred to PVDF membranes in 25 mM Tris, 92 mM glycine containing 20% (v/v) methanol at 110 V for 1 h. Following transfer, membranes were placed for 1 h in blocking buffer (bovine serum albumin 3% in T-TBS). For tyrosinase detection, membranes were probed first with 10 ml of blocking buffer containing goat anti-tyrosinase polyclonal antibody (Santa Cruz Biotechnology Inc., CA) (1:500) for 1 h at 27°C, followed by 10 ml of blocking buffer containing horseradish peroxidase-conjugated rabbit anti-goat IgG (1:5000) for 60 min at 27°C. Protein bands were visualized using luminol-based enhanced chemo-luminescence as described by the manufacturer (Perkin-Elmer Life Sciences). Densitometric analysis was performed using Scion Image (PC version of Macintosh-compatible NIH Image).
Tyrosinase activity assay
Cell monolayers were treated with trypsin/EDTA; suspensions washed with PBS and pellets recovered by centrifugation at 250 × g for 10 min. Cells were lysed by sonication (six times for 5 seconds each) in 0.5 ml of 0.1 M Na-phosphate buffer, pH 6.8, containing 0.1 mM PMSF. After centrifugation at 7,000 × g for 10 min, tyrosinase activity was assayed on supernatant according to Iozumi et al. . Fifty μl of sample was incubated in 0.5 ml of a reaction mixture containing 0.1 mM L-tyrosine, 2 μCi per ml of [3H] tyrosine, 0.1 mM L-DOPA and 0.1 mM PMSF in sodium phosphate buffer 0.1 M (pH 6.8). After 2 h at 37°C, the reaction was terminated by the addition of 1 ml of charcoal (10% wt/vol in 0.1 N HCl). Samples were centrifuged at 2000 g for 10 min, the supernatant was removed and mixed with scintillation cocktail, and radioactivity was determined using the LS 6500 scintillation system (Beckman, U.S.A.).
Treatment with cytotoxic agents
Cells were incubated with 30 μM DHBA or BSO in RPMI 1640 medium with 10% (v/v) FBS in humidified incubator with 5% CO2 at 37°C. After 48 h incubation cell viability was determined by MTT method, as previously described.
For tissue culture assays a set of at least four different experiment was performed and each data point within any single experiment is the mean (± SD) of eight independent replicas. P values for cell proliferation and cell viability were calculated respect to the corresponding value T = 0. the normal data distribution among samples was assessed by the Shapiro – Wilk test and the Parametric (T Student) or non-Paramentric (Mann-Whitney) test were used accordingly. Standard deviations (SD) were reported for cell specific activity ratios and for the relative tyrosinase expression.
The isolated E5 HPV 16 oncogene can be expressed in melanoma cells
E5 expression modulates endosomal pH and restores tyrosinase activity
The expression of HPV 16 E5 oncogene does not modulate tyrosinase mRNA nor protein levels
The tyrosinase reactivation could be exploited as a target for the development of selective chemotherapeutic agents
Pigment deposition takes place in specialized organelles, the melanosomes. In these organelles a number of specific proteins are expressed. Interestingly each of these proteins represents a unique feature of melanocytes and a potential target for the development of selective therapies or elective diagnostic methods for the malignant melanoma [41, 42]. Regulation of melanogenesis at transcriptional level is mostly controlled by the microphtalmia transcription factor, however the amelanotic phenotype may also result from post-translational mechanisms in cells expressing normal amounts of pigmentary proteins. This regulatory level has been shown to be important in determining skin and hair colour and pigmentary phenotype of malignant melanomas [37, 24].
The fast growing incidence of malignant melanomas in the last decades coupled with the lack of satisfactory treatments for advanced melanomas underline the urgency for a better understanding of their biology and greatly stimulated research in this area. To investigate the possibility to modulate the biological behaviour of amelanotic melanomas through the modulation of the organellar pH, we expressed the HPV 16 E5 oncogene in the FRM and M14 cells and evaluated the implications of such an expression on the cell phenotype. Both are amelanotic cell lines expressing normal levels of tyrosinase maintained in an inactive state by the acidic endosomal pH, as demonstrated by the tyrosinase restoration following the selective inhibition of the V-ATPase by ConA treatment.
The HPV 16 E5 oncogene is a small, highly hydrophobic protein of 83 aminoacids that localizes in endocellular membrane and exhibits only weak transforming activity [6, 43]. Within the context of the viral genome it has the function of enhancing the ligand dependent EGF Receptor activation  thus resulting in a longer persisting, higher producing viral infection. Once expressed as isolated protein, E5 is mostly found in the endoplasmic reticulum (ER) membranes and at a much lower abundance in the Golgi membranes and endosomes. In ER, through a hydrophobic interaction, the E5 protein would stably associate with 16 kDa subunit of V-ATPase, preventing its assembly into the mature form and therefore suppressing the endosomal acidification . However there is no generalized consent on this mechanism and other authors, based on the failure to induce V-ATPase inhibition in some models  and on the report that E5 disrupts actin filaments in fibroblasts , proposed that E5-mediated suppression of the endosomal acidification occurs through the disruption of the membrane trafficking responsible for the fusion of early endosomes with the highly acidic mature para-nuclear endosomes. Moreover other E5 indirect mechanisms may be hypothesised based on its complex modulation of cell proteome and membrane lipids and proteins composition [45–47].
Following the infection with a retrovirus construct bearing the HPV-16 E5 sequence, the E5 specific mRNA could be consistently detected in FRM and M14 cells up to thirty days post infection. The E5 viral specific mRNA was expressed at a level comparable with the one of the GAPDH housekeeping reference gene. The E5 expression was well tolerated with almost no cytotoxic effect and no modification of cell morphology. Expectedly, as revealed by experiments with AO, the E5 expression was associated with a relevant modification of the endocellular pH and with a neat re-activation of the tyrosinase enzyme. These data are in favour of the hypothesis that E5 protein does indeed act through an interaction with 16 kDa subunit c of the V0-ATPase sub-complex. In fact, in amelanotic melanomas the most of tyrosinase and of other melanogenic proteins, instead of being transported to the Golgi and endosomes for further processing and glicosilation, due to the acidic environment, are retained in the ER where they are rapidly degraded by proteasome . Conversely, the maturation of tyrosinase to the enzymatically active form (figure 4b) indicate the elevation of the endocellular pH to a near neutral value following the V-ATPase complex inhibition thus supporting the hypothesis of an interaction of the E5 with the 16 kDa sub unit c. This interaction could reasonably occurs in the ER where the 16 kDa V-ATPase subunit is synthesized and where most of E5 is localized. However we could not provide a positive evidence for a direct interaction and, considering the multifaceted cellular effects of E5, other indirect mechanisms may be envisioned. Namely the modifications of membrane lipids compositions and functions [45, 46] and the deep modifications of cell transcriptome , both obtained in HaCaT cells, have the potentials, either alone or in combination, to modulate the proteins and organellar functions without implying any direct physical E5/subunit c interaction.
The E5 expressing cells proved able to sustain the melanin deposition and to survive in anchorage independent culture conditions (figure 4c) thus confirming and extending the observation on mouse embryo fibroblasts  and human epithelial HaCaT cells  already reported. According to Zhang et al , these two features are associated with a reduced growth ability and represent the hallmark of melanomas adapted to grow in well oxygenated tissues. Conversely, a high growth rate, the ability to grow in adherence as in compact lesions and the lack of pigmentary activity (as a consequence of the environment acidification due to the high levels of glycolytic activity -the Warburg effect-), are typical of those melanomas adapted to grow in highly hypoxic condition of fast growing metastases. In this perspective the discussed results are consistent with the hypothesis of a more differentiated phenotype. Indeed following E5 expression and the restoration of a near neutral pH, in addition to the correct maturation of tyrosinase, a global re-organization of the endocellular trafficking occurs. Such a reorganization permits the adequate processing of the many pigmentary proteins through several different pathways and their correct cooperation into the multi-step process of pigment deposition. As a whole these data stand against the hypothesis that the E5 alkalinisation of cellular pH takes place through the subversion of endocellular trafficking, which is on the contrary restored, at least as far as melanogenesis is concerned. Conversely they support the view that the E5 protein, once expressed in an intact human cell, directly or indirectly modulates V-ATPase proton pump with a wide range of orchestrated functional consequences. Finally restoration of the melanogenic phenotype is associated with a clear elevation of cell reducing activity, consistent with a partially re-differentiated phenotype. Once again this result is in line with the hypothesis of a close linkage between the global melanoma phenotype and the cell metabolism which impacts on growth abilities, pathways activation and pigment deposition [36, 37].
Being the anaplastic phenotype of melanomas associated with a less favourable clinical outcome and a more severe prognosis , we next wondered whether such a reversion could have an impact on response to chemotherapeutic agents. In this work we showed that following the inhibition of V-ATPase by HPV16-E5 the whole melanin synthesis pathway is restored in amelanotic melanoma lines and accordingly these cells appear more responsive to dopamine-mimetic pro-drugs, whose toxicity is related to their oxidation into toxic intermediates i.e. quinones, by tyrosinase-catalyzed reactions. In addition, tyrosinase reactivation is also linked with an increased sensitivity to drugs interacting with other related pathways, as shown by the case of BSO, a GSH depleting drug via the gamma-glutamyl-cysteine synthetase inhibition. Since GSH is a major defence against toxic quinone intermediates through the production of conjugates, GSH depletion results in a severe cell death selectively in those cells where active melanogenesis is present.
In conclusion the expression of the HPV16-E5 oncogene proved able to (partially) revert the malignant phenotype of amelanotic melanomas to a less aggressive, drug responsive state.
This study was supported in part by a grant from the Ministry of Health of Italy. The authors would like to thank Dr Gary Sibbett (The Beatson Institute for Cancer Research, Glasgow, UK) for having kindly provided the plasmids for retrovirus production, Dr Gabriella Zupi (Regina Elena Cancer Institute) for having kindly supplied the M14 and FRM cell lines, Dr. Daniela Di Sciullo, Mr. Vincenzo Peresempio for their skilled technical assistance. Dr Irene Terrenato for her help with statistical work and Dr Marco Ravaioli for linguistic revision of the manuscript.
- zur Hausen H: Papillomavirus infections–a major cause of human cancers. Biochim Biophys Acta. 1996, 1288: F55-78.Google Scholar
- zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002, 2: 342-50. 10.1038/nrc798.View ArticleGoogle Scholar
- Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989, 63: 4417-21.Google Scholar
- Thomas M, Pim D, Banks L: The Role of HPV E6 Oncoprotein in Malignant Progression. Papillomavirus Research – From natural history to Vaccines and Beyond. Edited by: Campo MS. 2006, Norfolk: Caister Academic Press, 115-132.Google Scholar
- McCance DJ: The Biology of the E7 Protein of HPV16. Papillomavirus Research – From natural history to Vaccines and Beyond. Edited by: Campo MS. 2006, Norfolk: Caister Academic Press, 133-144.Google Scholar
- Leptak C, Ramon y Cajal S, Kulke R, Horwitz BH, Riese DJ, Dotto GP, DiMaio D: Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J Virol. 1991, 65: 7078-83.Google Scholar
- Bouvard V, Matlashewski G, Gu ZM, Storey A, Banks L: The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology. 1994, 203: 73-80. 10.1006/viro.1994.1456.View ArticleGoogle Scholar
- Valle GF, Banks L: The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol. 1995, 76: 1239-45. 10.1099/0022-1317-76-5-1239.View ArticleGoogle Scholar
- Bravo IG, Alonso A: Mucosal Human Papillomaviruses Encode Four Different E5 Proteins Whose Chemistry and Phylogeny Correlate with Malignant or Benign Growth. J Virology. 2004, 78: 13613-13626. 10.1128/JVI.78.24.13613-13626.2004.View ArticleGoogle Scholar
- Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD: The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005, 337: 76-84. 10.1016/j.virol.2005.04.002.View ArticleGoogle Scholar
- Conrad M, Bubb VJ, Schlegel R: The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol. 1993, 67: 6170-8.Google Scholar
- Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A: The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res. 1998, 241: 76-83. 10.1006/excr.1998.4024.View ArticleGoogle Scholar
- Gu Z, Matlashewski G: Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J Virol. 1995, 69: 8051-6.Google Scholar
- Chen SL, Mounts P: Transforming activity of E5a protein of human papillomavirus type 6 in NIH 3T3 and C127 cells. J Virol. 1990, 64: 3226-33.Google Scholar
- Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS: E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer. 2005, 113: 276-83. 10.1002/ijc.20558.View ArticleGoogle Scholar
- Zhang B, Li P, Wang E, Brahmi Z, Dunn KW, Blum JS, Roman A: The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma. Virology. 2003, 310: 100-8. 10.1016/S0042-6822(03)00103-X.View ArticleGoogle Scholar
- Suprynowicz FA, Disbrow GL, Simic V, Schlegel R: Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16?. Virology. 2005, 332: 102-13. 10.1016/j.virol.2004.11.011.View ArticleGoogle Scholar
- Rodriguez MI, Finbow ME, Alonso A: Binding of human papillomavirus 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H+-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene. 2000, 19: 3727-32. 10.1038/sj.onc.1203718.View ArticleGoogle Scholar
- Graham LA, Powell B, Stevens TH: Composition and assembly of the yeast vacuolar H(+)-ATPase complex. J Exp Biol. 2000, 203: 61-70.Google Scholar
- Straight SW, Hinkle PM, Jewers RJ, McCance DJ: The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol. 1993, 67: 4521-32.Google Scholar
- Straight SW, Herman B, McCance DJ: The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol. 1995, 69: 3185-92.Google Scholar
- Adam JL, Briggs MW, McCance DJ: A mutagenic analysis of the E5 protein of human papillomavirus type 16 reveals that E5 binding to the vacuolar H+-ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. Virology. 2000, 272: 315-25. 10.1006/viro.2000.0376.View ArticleGoogle Scholar
- Thomsen P, van Deurs B, Norrild B, Kayser L: The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene. 2000, 19: 6023-32. 10.1038/sj.onc.1204010.View ArticleGoogle Scholar
- Ancans J, Tobin DJ, Hoogduijn MJ, Smit NP, Wakamatsu K, Thody AJ: Melanosomal pH controls rate of melanogenesis, eumelanin/phaeomelanin ratio and melanosome maturation in melanocytes and melanoma cells. Exp Cell Res. 2001, 268: 26-35. 10.1006/excr.2001.5251.View ArticleGoogle Scholar
- Fuller BB, Spaulding DT, Smith DR: Regulation of the catalytic activity of preexisting tyrosinase in black and Caucasian human melanocyte cell cultures. Exp Cell Res. 2001, 262: 197-208. 10.1006/excr.2000.5092.View ArticleGoogle Scholar
- Ancans J, Thody AJ: Activation of melanogenesis by vacuolar type H(+)-ATPase inhibitors in amelanotic, tyrosinase positive human and mouse melanoma cells. FEBS Lett. 2000, 478: 57-60. 10.1016/S0014-5793(00)01795-6.View ArticleGoogle Scholar
- De Marco F, Perluigi M, Marcante ML, Coccia R, Foppoli C, Blarzino C, Rosei MA: Cytotoxicity of dopamine-derived tetrahydroisoquinolines on melanoma cells. Biochem Pharmacol. 2002, 64: 1503-12. 10.1016/S0006-2952(02)01353-9.View ArticleGoogle Scholar
- Bowman EJ, Siebers A, Altendorf K: Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA. 1988, 85: 7972-6. 10.1073/pnas.85.21.7972.View ArticleGoogle Scholar
- Drose S, Bindseil KU, Bowman EJ, Siebers A, Zeeck A, Altendorf K: Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry. 1993, 32: 3902-6. 10.1021/bi00066a008.View ArticleGoogle Scholar
- Ashrafi GH, Tsirimonakis E, Marchetti B, O'Brien P, Sibbet GJ, Andrew L, Campo MS: Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene. 2002, 21: 248-259. 10.1038/sj.onc.1205008.View ArticleGoogle Scholar
- Mann R, Mulligan RC, Baltimore D: Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell. 1983, 33: 153-9. 10.1016/0092-8674(83)90344-6.View ArticleGoogle Scholar
- Calogero A, Timmer-Bosscha H, Schraffordt Koops H, Tiebosch AT, Mulder NH, Hospers GA: Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes. Br J Cancer. 2000, 83: 184-7. 10.1054/bjoc.2000.1282.View ArticleGoogle Scholar
- Gerlier D, Thomasset N: Use of MTT colorimetric assay to measure cell activation. J Immunol Methods. 1986, 94: 57-63. 10.1016/0022-1759(86)90215-2.View ArticleGoogle Scholar
- De Marco F, Di Lonardo A, Venuti A, Marcante ML: Interferon inhibition of neoplastic phenotype in cell lines harbouring human papillomavirus sequences. J Biol Regul Homeost Agents. 1991, 5: 65-70.Google Scholar
- Palmgren MG: Acridine orange as a probe for measuring pH gradients across membranes: mechanism and limitations. Anal Biochem. 1991, 192: 316-21. 10.1016/0003-2697(91)90542-2.View ArticleGoogle Scholar
- Foppoli C, De Marco F, Blarzino C, Perluigi M, Cini C, Coccia R: Biological response of human diploid keratinocytes to quinone-producing compounds: role of NAD(P)H:quinone oxidoreductase 1. Int J Biochem Cell Biol. 2005, 37: 852-63. 10.1016/j.biocel.2004.11.002.View ArticleGoogle Scholar
- Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB: Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol. 1993, 100: 806-11. 10.1111/1523-1747.ep12476630.View ArticleGoogle Scholar
- Halaban R: Pigmentation in melanomas: Changes manifesting underlying oncogenic and metabolic activities. Oncol Res. 2002, 13: 3-8.Google Scholar
- Zhang W, Tsan R, Nam DH, Lu W, Fidler IJ: Loss of adhesion in the circulation converts amelanotic metastatic melanoma cells to melanotic by inhibition of AKT. Neoplasia. 2006, 8: 543-50. 10.1593/neo.05655.View ArticleGoogle Scholar
- Prezioso JA, Fitzgerald GB, Wick MM: Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells. Pigment Cell Res. 1990, 3: 49-54. 10.1111/j.1600-0749.1990.tb00322.x.View ArticleGoogle Scholar
- Orlow SJ, Silvers WK, Zhou BK, Mintz B: Comparative decreases in tyrosinase, TRP-1, TRP-2, and Pmel 17/silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases. Cancer Res. 1998, 58: 1521-3.Google Scholar
- Takeuchi H, Kuo C, Morton DL, Wang HJ, Hoon DS: Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res. 2003, 63: 441-8.Google Scholar
- DiMaio D, Mattoon D: Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene. 2001, 20: 7866-73. 10.1038/sj.onc.1204915.View ArticleGoogle Scholar
- Ashby AD, Meagher L, Campo MS, Finbow ME: E5 transforming proteins of papillomaviruses do not disturb the activity of the vacuolar H(+)-ATPase. J Gen Virol. 2001, 82: 2353-62.View ArticleGoogle Scholar
- Bravo IG, Crusius K, Alonso A: The E5 protein of the human papillomavirus type 16 modulates composition and dynamics of membrane lipids in keratinocytes. Arch Virol. 2005, 150: 231-46. 10.1007/s00705-004-0420-x.View ArticleGoogle Scholar
- Suprynowicz FA, Disbrow GL, Krawczyk E, Simic V, Lantzky K, Schlegel R: HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene. 2008, 27: 1071-1078. 10.1038/sj.onc.1210725.View ArticleGoogle Scholar
- Kivi N, Greco D, Auvinen P, Auvinen E: Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene. 2008, 27: 2532-41. 10.1038/sj.onc.1210916.View ArticleGoogle Scholar
- Watabe H, Valencia JC, Yasumoto K, Kushimoto T, Ando H, Muller J, Vieira WD, Mizoguchi M, Appella E, Hearing VJ: Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity. J Biol Chem. 2004, 279: 7971-81. 10.1074/jbc.M309714200.View ArticleGoogle Scholar
- Lewis C, Baro MF, Marques M, Grüner M, Alonso A, Bravo IG: The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth. Virol J. 2008, 5: 30-10.1186/1743-422X-5-30.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.